Solventum (NYSE:SOLV) Releases FY 2026 Earnings Guidance

Solventum (NYSE:SOLV) updated its FY 2026 earnings guidance on Tuesday. The company provided earnings per share (EPS) guidance of 6.600-6.600 for the period, compared to the consensus estimate of 6.470. The company issued revenue guidance of -.

Analyst Ratings Changes

Several equities analysts recently weighed in on SOLV shares. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Solventum in a research report on Tuesday, January 27th. Wells Fargo & Company raised Solventum to a “hold” rating in a report on Wednesday, March 18th. Mizuho set a $100.00 price objective on Solventum and gave the stock an “outperform” rating in a report on Tuesday, January 20th. Piper Sandler decreased their price objective on Solventum from $98.00 to $92.00 and set an “overweight” rating for the company in a report on Friday, April 17th. Finally, KeyCorp decreased their price objective on Solventum from $99.00 to $92.00 and set an “overweight” rating for the company in a report on Monday, April 27th. Seven research analysts have rated the stock with a Buy rating, five have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $89.45.

Solventum Stock Performance

Shares of NYSE SOLV traded up $1.65 during midday trading on Tuesday, reaching $69.09. The company’s stock had a trading volume of 1,944,083 shares, compared to its average volume of 1,217,484. Solventum has a 12-month low of $62.38 and a 12-month high of $88.20. The firm has a 50 day moving average price of $67.99 and a 200-day moving average price of $74.53. The stock has a market capitalization of $11.98 billion, a P/E ratio of 7.79, a PEG ratio of 1.09 and a beta of 0.59. The company has a debt-to-equity ratio of 1.00, a current ratio of 1.23 and a quick ratio of 0.89.

Solventum (NYSE:SOLV) last announced its earnings results on Tuesday, May 5th. The company reported $1.48 earnings per share for the quarter, topping analysts’ consensus estimates of $1.35 by $0.13. Solventum had a return on equity of 25.26% and a net margin of 18.69%.The firm had revenue of $2.01 billion for the quarter, compared to the consensus estimate of $1.97 billion. Solventum has set its FY 2026 guidance at 6.600-6.600 EPS. As a group, equities analysts predict that Solventum will post 6.5 earnings per share for the current year.

Insider Buying and Selling at Solventum

In other Solventum news, Director Amy Mcbride Wendell bought 1,475 shares of the business’s stock in a transaction dated Tuesday, March 10th. The shares were purchased at an average price of $68.03 per share, for a total transaction of $100,344.25. Following the purchase, the director directly owned 5,039 shares of the company’s stock, valued at approximately $342,803.17. This represents a 41.39% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.24% of the stock is owned by insiders.

Key Solventum News

Here are the key news stories impacting Solventum this week:

• Positive Sentiment: Q1 earnings beat — Solventum reported adjusted EPS of $1.48 vs. $1.35 consensus and revenue of $2.01B vs. $1.97B expected, supporting today’s upside. Read More.
• Positive Sentiment: Guidance raised/confirmed — management set FY2026 EPS at 6.600 (narrow range) vs. street ~6.47, and signaled adjusted EPS toward the high end of prior range, which helps justify higher valuations. Read More.
• Positive Sentiment: Organic growth & cash flow affirmed — reported sales fell slightly but organic sales rose ~2.1% and management reaffirmed full‑year organic sales growth and free cash flow guidance, an encouraging sign for core business momentum. Read More.
• Neutral Sentiment: Analyst sentiment remains cautious — consensus analyst recommendation reported as “Hold,” indicating some investors/analysts want to see sustained improvement before upgrading. Read More.
• Neutral Sentiment: Investor materials available — company posted the earnings release and slide deck (useful for models and calls); this transparency reduces uncertainty but doesn’t change fundamentals by itself. Read More.
• Negative Sentiment: Reported revenue decline — on a reported basis sales declined ~3.0% year‑over‑year, a reminder that headline growth still faces pressure in parts of the business. Read More.
• Negative Sentiment: Macro/tech concerns flagged — coverage notes AI‑related risks and margin pressure that could test Solventum’s turnaround narrative and future margin expansion. Investors should watch commentary on AI exposure and cost actions in upcoming calls. Read More.

Hedge Funds Weigh In On Solventum

Institutional investors have recently bought and sold shares of the company. CrossGen Wealth LLC purchased a new position in Solventum in the fourth quarter valued at approximately $25,000. Measured Wealth Private Client Group LLC purchased a new position in Solventum in the third quarter valued at approximately $25,000. CYBER HORNET ETFs LLC purchased a new position in Solventum in the second quarter valued at approximately $28,000. MUFG Securities EMEA plc purchased a new position in Solventum in the second quarter valued at approximately $31,000. Finally, State of Wyoming bought a new position in shares of Solventum in the second quarter worth $33,000.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.